JULY 2026 SEE FULL NEWSLETTER By Dr. Pablo Gulayin y Dr. Vilma Irazola* High blood pressure is the leading modifiable risk factor for cardiovascular and cerebrovascular disease. The 2019 Global Burden of Disease Study estimated that it was responsible for approximately ten million deaths, contributing substantially to the burden of cardiovascular disease.
MAY 2026 SEE FULL NEWSLETTER By Prof. Dr. Andrés Pichon Riviere, General Director of IECS In a scenario where health systems face increasing challenges, the production of rigorous knowledge alone is no longer enough. The central challenge today is to ensure that this evidence informs concrete, timely, and sustainable decisions. That is where
IECS 2026-2030: A step towards organizational maturity See more "
DECEMBER 2025 SEE FULL NEWSLETTER By Mag. Cintia Cejas, Dr. Santiago Esteban and Dr. Martín Sabán* The value of AI lies not in chasing technological trends, but in solving problems that matter. Artificial intelligence has earned its place on the health agenda. But between the promises of “revolution” and the warnings of
AI and health: innovation without illusions, responsibility without excuses See more "
OCTOBER 2025SEE FULL NEWSLETTER By Dr. Viviana E. Rodriguez* Antimicrobial resistance (AMR) is a priority threat to public health, driven by the inappropriate use of antimicrobials in human health, animal health, agriculture, and their dissemination in the environment. In 2019, an estimated 4,95 million deaths were related to AMR.
Antimicrobial resistance: a threat requiring immediate and collaborative action See more "
APRIL 2025 SEE FULL NEWSLETTER In a context of increasingly better but more expensive medical innovations, it is important to strengthen evidence-based decision-making. The creation of ANEFiTS plays a key role in beginning to address this gap. What are the proven benefits of a new drug, vaccine, test, procedure, or biomedical device?
2025: A pivotal year in health technology assessment in Argentina? See more "
AUGUST 2025SEE FULL NEWSLETTER By representatives of the local organization of the HTAi 2025 Annual Congress (IECS) In a context where health systems face structural challenges, persistent inequalities and increasingly complex decisions, from the IECS we renew our commitment to a central task: generating rigorous evidence, training committed professionals and forging networks
HTAi 2025 in Buenos Aires: Evidence and Commitment in Complex Times See more "
DECEMBER 2024SEE COMPLETE NEWSLETTER With more than 1.100 professionals who have completed the program, the UBA Master's in Clinical Effectiveness has impacted the way of thinking about health in our country and in Latin America. Master's Team In May 1996, while walking down Broadway and Fifth Avenue in New York City, the UBA Master's in Clinical Effectiveness was a great opportunity to learn about the importance of clinical effectiveness.
The PEC turns 25 years old See more "
SEPTEMBER – OCTOBER 2024SEE FULL NEWSLETTER Ensuring that people can receive the medicines they need is an ethical and health imperative that requires the collaboration of multiple actors: governments, health institutions, pharmaceutical companies, and civil society organizations. Medicines improve quality of life, reduce mortality, and are key to
Access to medicines: a fundamental pillar of health systems See more "
JULY – AUGUST 2024SEE FULL NEWSLETTER On the eve of World Evidence-Based Health Day (EBHC), it is necessary to highlight the importance of a comprehensive approach to address the polycrisis and transform knowledge into action. World Evidence-Based Health Day (EBHC), which is celebrated this year, is a day of great interest for health professionals and the public.
Evidence has always been necessary, but it also has to arrive in a timely manner See more "
MAY – JUNE 2024SEE COMPLETE NEWSLETTER A validated questionnaire that has already been answered by around 6.000 people, revealed that 60% have a moderate or high risk of developing the disease. Worldwide, almost 1 in 10 adults between 20 and 79 years old live with diabetes. And in Argentina in particular the prevalence of
Identification of diabetes risk in the population: a field experience See more "
